<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>kissinger_ex4.txt
<DESCRIPTION>EXHIBIT 99.4
<TEXT>


Exhibit 99.4

Demand and Notification Letter from Peter T. Kissinger, Ph.D. and Candice B.
Kissinger to the Board of Directors of Bioanalytical Systems, Inc.




                             PETER T. KISSINGER, PH.D. AND CANDICE B. KISSINGER
                                                               111 Lorene Place
                                             West Lafayette, Indiana 47906-8620

July 29, 2009

Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906
Attention:  Corporate Secretary

               Re:  Demand for Special Meeting of Shareholders and Notice of
                    Nomination of Directors

Ladies and Gentlemen:

     Please accept this letter as our written demand for a special meeting of
the shareholders (the "Special Meeting") of Bioanalytical Systems, Inc. (the
"Company") for the purpose of: (i) removing all directors of the Company other
than Larry S. Boulet, including, without limitation, removing William E.
Baitinger, David W. Crabb, Leslie B. Daniels and Richard M. Shepperd (or any
of their successors), and any other directors now or hereafter appointed prior
to the Special Meeting; and (ii) electing four new directors to fill the
vacancies created by such removal. In accordance with Article II, Section 2.2
of the Company's Amended and Restated By-laws, a special meeting of the
shareholders shall be called upon delivery to the Secretary of the Company of
a written demand signed and dated by the holders of at least 25% of all the
votes entitled to be cast on any issue proposed to be considered at that
meeting.  As the holders of 26% of the outstanding shares of the Company's
common stock, we hereby request that the  Board of Directors call the Special
Meeting as promptly as possible after receipt of this demand. We believe that
the Special Meeting could reasonably be held within 45 days from the date
hereof.

     Please also accept this letter as written notice of our intent to make a
nomination at the Special Meeting of the following four persons (each, a
"Nominee" and collectively, the "Slate") for election as directors to fill
the vacancies created by the removal of four of the current directors:
John B. Landis, Ph.D., Joseph H. Broecker, Candice B. Kissinger and Jerome
G. Marchant.

     The following information is being provided in accordance with Article
III, Section 3.2.1 of the Company's Amended and Restated By-laws:

     Information Regarding the Shareholders Providing this Notice (the
"Kissingers"):

     (1)  Biographical information:

          Name:                  Peter T. Kissinger, Ph.D.
          Age:                   64
          Business Address:      Department of Chemistry, Purdue University,
                                 West Lafayette, IN 47907
          Residence Address:     111 Lorene Place, West Lafayette, IN
                                 47906-8620
          Principal Occupation:  See biographical information below

          Name:                  Candice B. Kissinger
          Age:                   57
          Business Address:      Phlebotics, Inc., 1305 Cumberland Avenue, West
                                 Lafayette, IN 47906-1316
          Residence Address:     111 Lorene Place, West Lafayette, IN
                                 47906-8620
          Principal Occupation:  See biographical information below

      Peter T. Kissinger, Ph.D. has served as a Professor of Chemistry in the
      Department of Chemistry at Purdue University since 1975.  He has also
      served as the Chief Executive Officer of Prosolia, Inc., a life sciences
      company that develops, manufactures, and markets analytical chemistry
      tools that enhance and expand the use of mass spectrometers, since June
      2007.  In 2007, Dr. Kissinger and Ms. Kissinger founded Phlebotics, Inc.
      ("Phlebotics"), a start-up medical device manufacturer focused on
      diagnostic information for intensive care medicine.  Dr. Kissinger
      founded the Company in 1974 and served as President and Chief Executive
      Officer until September 2006, as Chairman of the Board until September
      2007 and as Chief Scientific Officer from October 2006 until June 2007.
      Dr. Kissinger earned a B.S. degree in Chemistry from Union College and a
      Ph.D. in Analytical Chemistry from the University of North Carolina in
      Chapel Hill.

      Candice B. Kissinger currently serves as the Chief Scientific Officer for
      Phlebotics, which she founded in 2007 with Dr. Kissinger.  From August
      2007 until June 2009, she was the Legacy Products Coordinator at The Chao
      Center, a subsidiary of the Purdue Research Foundation, where she oversaw
      the North American supply and support of the prescription antibiotic
      Seromycin(R).  As an adjunct Associate Professor of Industrial and
      Physical Pharmacy at Purdue University since October 2007 and a
      faculty member with the Bindley Biosciences Center at Purdue since
      May 2009, she conducts research on new treatments for latent and active
      tuberculosis (TB), with special emphasis on new drug formulations
      suitable for infants and young children.  Prior to joining The Chao
      Center, Ms. Kissinger worked at the Company for 29 years, serving in
      multiple positions, most recently as Senior Vice President of Research
      from January 2000 until June 2007.  During her tenure, Ms. Kissinger
      obtained seven U.S. and international patents for Company products,
      including the Culex(R) Automated Blood Sampler.  Ms. Kissinger also was
      a member of the Company's board of directors and served as the Corporate
      Secretary of the Company from November 1978 until September 2007.  Prior
      to joining the Company, she was a researcher in the Fermentation group,
      Fine Chemical Division of The Upjohn Company from 1975 until 1978, where
      she earned her first eight patents. Ms. Kissinger earned a M.S. degree in
      Food Science/Industrial Microbiology from the University of
      Massachusetts and a B.A. degree in Bacteriology from Ohio Wesleyan
      University.

      (2)  Beneficial ownership of securities of the Company as of the date of
this notice:
                                          Amount and Nature of
Title of Class  Name of Beneficial Owner  Beneficial Ownership  Percent of Class

Common Stock    Peter T. Kissinger        1,275,767 (a)         26.0 (a)(b)

Common Stock    Candice B. Kissinger      1,275,767 (c)         26.0 (b)(c)

          _____________
          (a)  Dr. Kissinger has sole voting and dispositive power over 427,547
               of these shares and shares voting and dispositive power over
               848,220 of these shares with his spouse, including 1,354 shares
               indirectly held by Ms. Kissinger as custodian for the benefit of
               their children.
          (b)  Based on 4,915,318 shares of the Company's common stock which
               were outstanding as of May 1, 2009.
          (c)  Ms. Kissinger has sole voting and dispositive power over 252,310
               of these shares, including 1,354 shares indirectly held by
               Ms. Kissinger as custodian for the benefit of their children,
               and shares voting and dispositive power over 1,023,457 of these
               shares with her spouse.

      (3)  Arrangements regarding the nominations and transactions with the
Company:

           Ms. Kissinger is one of the Nominees and is also one of the
           shareholders demanding the Special Meeting and proposing the Slate.
           Otherwise, there are no arrangements or understandings between us
           and any Nominee or any other person or persons pursuant to which
           the nominations are to be made by us.

           Ms. Kissinger is the spouse of Dr. Kissinger, the Chairman Emeritus
           of the Board of Directors of the Company, a non-voting,
           uncompensated position.  As Chairman Emeritus, Dr. Kissinger was
           supposed to be permitted to attend Board meetings and provide input
           into the matters coming before the Board.  Since January 2008,
           however, Dr. Kissinger has not been included in any matters coming
           before the Board and has not been invited to participate in Board
           meetings.

           In connection with the resignations of the Kissingers from the
           Company in 2007, the Company entered into a Severance Agreement
           and Release of All Claims (a "Severance Agreement") with each of
           the Kissingers. The Severance Agreements required the Company to
           pay $175,000, less tax and deductions required by law, to each of
           the Kissingers. This amount was paid in the form of a lump sum
           payment of $87,500 to each of the Kissingers on the first regular
           payroll date after October 5, 2007, with the remainder paid in
           six equal monthly installments, beginning November 2007 and ending
           April 2008. The Kissingers were also entitled to receive a payment
           equal to the monthly cost of maintaining health insurance for
           themselves and their dependents for 12 months. The Severance
           Agreements also contain confidentiality, non-disparagement and
           non-solicitation provisions for the benefit of the Company.

           On September 28, 2007, the Company entered into a License Agreement
           with Phlebotics (the "License Agreement"). The License Agreement
           provided for a license by the Company to Phlebotics of two of the
           Company's patent applications and their related know-how related to
           portable sampling and drug delivery devices.  As stated above,
           Phlebotics was founded by the Kissingers, and the Company entered
           into the License Agreement in connection with their resignations.
           No amounts were payable to the Kissingers under the License
           Agreement.  Under the terms of the License Agreement, if the
           Company decided to abandon the prosecution of either of the patent
           applications, Phlebotics had the right to take ownership of the
           abandoned patent application and to continue the prosecution
           thereof.  The Company notified Phlebotics that it was going to
           abandon one of the patent applications, and Phlebotics exercised
           its right to acquire title to the patent application.  The
           assignment of the patent application from the Company to Phlebotics
           was made effective as of June 17, 2009.  Concurrently with the
           assignment of the patent application, the License Agreement was
           terminated.

      (4)  Attendance at the Special Meeting:

           We hereby represent that we intend to appear in person or by proxy
           at the Special Meeting to nominate the Slate.

      (5)  Shares purchased/sold in the last two years:

           Name                Date        Shares Sold

           Peter T. Kissinger  02/28/2008  300

           Peter T. Kissinger  02/29/2008  600

           Peter T. Kissinger  03/03/2008  500

           Peter T. Kissinger  03/04/2008  600

           Peter T. Kissinger  03/05/2008  500

           Peter T. Kissinger  03/06/2008  100

           Peter T. Kissinger  03/07/2008  200

           Peter T. Kissinger  03/10/2008  200

           Peter T. Kissinger  03/11/2008  200

           Peter T. Kissinger  03/12/2008  200

           No shares were purchased by either of us in the last two years.  No
           shares were sold by Ms. Kissinger in the last two years.

       Information Regarding the Nominees:

       (1)  Biographical information:

            Name:                  John B. Landis, Ph.D.
            Age:                   56
            Business Address:      12240 Montcalm Street, Carmel, IN 46032
            Residence Address:     Same
            Principal Occupation:  See biographical information below

            Name:                  Joseph H. Broecker
            Age:                   63
            Business Address:      111 Monument Circle, Suite 1022,
                                   Indianapolis, IN 46204
            Residence Address:     5015 Fall Creek Road, Indianapolis, IN 46220
            Principal Occupation:  See biographical information below

            Name:                  Candice B. Kissinger
            Age:                   57
            Business Address:      Phlebotics, Inc, 1305 Cumberland Avenue,
                                   West Lafayette, IN 47906-1316
            Residence Address:     111 Lorene Place, West Lafayette, IN
                                   47906-8620
            Principal Occupation:  See biographical information above under
                                   "Information Regarding the Shareholders
                                   Providing this Notice"

            Name:                  Jerome G. Marchant
            Age:                   67
            Business Address:      N/A
            Residence Address:     N 7595 County Highway A, Green Lake, WI 54941
            Principal Occupation:  Retired.  See biographical information below

        John B. Landis, Ph.D. served as Senior Vice President, Pharmaceutical
        Sciences of Schering-Plough Corporation, a pharmaceutical company,
        from September 2003 until his retirement in October 2008.  In that
        role, Dr. Landis led the global pharmaceutical sciences function of
        pharmacy, analytical chemistry, process chemistry, biotechnology,
        quality assurance, clinical supplies and devices.  Prior to that,
        Dr. Landis served as Senior Vice President, Preclinical Development
        at Pharmacia Corporation from 1997 until 2003 and led the global
        preclinical functions of toxicology, drug metabolism and
        pharmacokinetics, pharmaceutical sciences, analytical chemistry and
        laboratory animal care.  Dr. Landis also served as Vice President,
        Central Nervous System (CNS) Psychiatry, Critical Care and Inflammation
        Development for Pharmacia & Upjohn from 1995 through 1997.  Prior to
        that, Dr. Landis was employed by The Upjohn Company, where he held
        positions of increasing responsibility in the areas of analytical
        research, quality assurance and quality control.  He is a current
        member of Purdue University's Chemistry Leadership Council and Dean's
        Leadership Council for the School of Science and serves on the
        Advisory Board of South West Michigan Life Science Venture Capital and
        NanoMed Scientific and on the board of directors of Metabolic Solutions
        Development Company.  Over his career, Dr. Landis served on several
        other boards of directors, academic advisory panels and
        professional boards.  Dr. Landis earned Ph.D. and M.S. degrees in
        Analytical Chemistry from Purdue University and a B.S. degree in
        Chemistry from Kent State University.

        Joseph H. Broecker co-founded Periculum Capital Company, LLC, an
        investment banking firm, in 1998 and serves as Senior Managing
        Director and head of the firm's private equity and merchant banking
        practice.  Prior to that, Mr. Broecker served as Senior Vice President
        and Managing Director of NatCity Investments, Inc., as well as its
        predecessor firm, Raffensperger, Hughes and Co.  Mr. Broecker
        co-founded two venture capital private equity partnerships and
        remains an active advisor to private equity firms throughout the
        Midwest.  Earlier in his career, Mr. Broecker served as a senior
        operating and corporate executive of Boehringer Mannheim GmbH, a
        European-based multi-national medical device and pharmaceutical
        company, and was a manager in the consulting division of Ernst and
        Young (a/k/a Ernst & Ernst).  Mr. Broecker is a Certified Public
        Accountant and has served as a director of a number of private and
        public companies primarily involved in the healthcare, chemical and
        consumer industries.  He graduated from the Executive Program at
        Indiana University and earned a B.B.A. in accounting and finance from
        the University of Notre Dame.

        Jerome G. Marchant, currently a private investor, retired as Chief
        Executive Officer of Butzin-Marchant Funeral Home in 1995, after
        serving in that position for 35 years. Mr. Marchant also served as
        Chief Executive Officer of Wildflower Monument Company from 1984 until
        1995. During his career, Mr. Marchant served on several boards of
        directors, including M&I Corp. from 1987 until 1996 and Central
        Federal Savings and Loan from 1979 until 1987.  He was active on the
        Building and Expansion committee for Central Federal Savings and
        Loan. Mr. Marchant earned a Bachelor of Music degree from the
        University of Wisconsin-Oshkosh and a Mortuary Science degree from the
        Milwaukee School of Mortuary Science. Mr. Marchant was Nationally
        Certified and has traveled the country extensively practicing
        Restorative Art.

        Other than Ms. Kissinger, each of the Nominees is independent under the
        independence standards applicable to the Company pursuant to Item
        407(a)(1) of Regulation S-K.

        (2)  Beneficial ownership of securities of the Company as of the
date of this notice:

                                          Amount and Nature of
Title of Class  Name of Beneficial Owner  Beneficial Ownership  Percent of Class

Common Stock    John B. Landis            ---                   0

Common Stock    Joseph H. Broecker         342                  * (a)

Common Stock    Candice B. Kissinger       1,275,767 (b)        26.0 (a)(b)

Common Stock    Jerome G. Marchant         95,066               1.9 (a)

             ___________
             *   Less than 1% of the outstanding shares of the Company's common
                 stock.
            (a)  Based on 4,915,318 shares of the Company's common stock which
                 were outstanding as of May 1, 2009.
            (b)  Ms. Kissinger has sole voting and dispositive power over
                 252,310 of these shares, including 1,354 shares indirectly
                 held by Ms. Kissinger as custodian for the benefit of their
                 children, and shares voting and dispositive power over
                 1,023,457 of these shares with her spouse.

        (3)  Shares purchased/sold in the last two years:

             None of the Nominees has purchased or sold any shares of the
             Company's common stock in the last two years.

        (4)  Consent.  The consent of each Nominee to serve as a director of
             the Company if so elected is attached hereto.

        (5)  Other interests in the election and relationships with the
Company:

             We and certain Nominees have an interest in the election of
             directors at the Special Meeting directly and/or indirectly
             through the beneficial ownership of shares of the Company's
             common stock, as described above.

             With respect to each of us and each Nominee, other than as
             disclosed in this notice, (i) such individual is not, nor was
             within the past year, a party to any contract, arrangement or
             understanding with any person with respect to any securities
             of the Company, including, but not limited to, joint ventures,
             loan or option arrangements, puts or calls, guarantees against
             loss or guarantees of profit, division of losses or profits,
             or the giving or withholding of proxies; and (ii) neither
             such individual nor any of such individual's associates have
             any arrangement or understanding with any person with respect
             to (a) any future employment by the Company or its affiliates,
             or (b) any future transactions to which the Company or any of
             its affiliates will or may be a party.

      Information is set forth herein as of the close of business on July 28,
2009. Neither the delivery of this notice nor any delivery by us or any Nominee
of additional information to the Company from and after the date hereof shall
be deemed to constitute an admission by any such person or any of their
respective affiliates (if any) that such delivery is required or that each
and every item or any item of information is required or as to the legality
or enforceability of any notice requirement or any other matter, or a waiver by
such person or any of their respective affiliates (if any) of their right to
contest or challenge, in any way, the validity or enforceability of any notice
requirement or any other matter (including actions taken by the Board of
Directors of the Company in anticipation of or following receipt of this
notice). Furthermore, if the Board of Directors of the Company increases the
number of directors to be nominated and elected at the Special Meeting, we
reserve the right to add additional director nominees in respect of each such
additional directorship.  In the event any statement or other information in
this notice is not true, or to the extent any applicable information has been
omitted from this notice, we and the Nominees reserve the right to correct
and/or supplement any such statement or other information set forth in this
notice.

     As a courtesy, we and the Nominees represent that we will notify the
Company in writing of the class and number of such shares owned of record and
beneficially (if any) as of the record date for the Special Meeting promptly
following the later of the record date or the date notice of the record date
is first publicly disclosed, however, such representation shall not be an
admission by us, any Nominee or any of our respective affiliates of the
legality thereof or that such delivery is required.

     We have filed a Schedule 13D under the Securities Exchange Act of 1934,
as amended (the "Exchange Act"), with the Securities and Exchange Commission
(the "SEC") relating to the Company (the "Filing").  The Filing, all
attachments and amendments thereto and all future amendments thereto, are
hereby incorporated into and made a part of this notice, but only to the
extent that the information disclosed therein constitutes information
regarding us that is required to be set forth in this notice pursuant to the
requirements set forth in the Amended and Restated Bylaws.  Accordingly, all
such matters disclosed in any part of the Filing, including all attachments
thereto, should be deemed disclosed for all purposes of this notice. The
Filing, a copy of which was previously delivered to the Company pursuant to
Rule 13d-7 under the Exchange Act, is available at no charge at the SEC's
website at http://www.sec.gov. If the Company requests additional copies of
the Filing, we will provide them, and original signed consents shall be
provided upon request by the Company.

     Please contact us immediately if the Company requires additional
information to determine eligibility of the proposed Nominees to serve as
directors of the Company, or if the Company determines that we must take
additional actions to ensure that the nomination and the demand for the
Special Meeting are made in accordance with the procedures described in the
Amended and Restated By-laws.

Sincerely,

/s/ Peter T. Kissinger, Ph.D.     /s/ Candice B. Kissinger

Peter T. Kissinger, Ph.D.         Candice B. Kissinger



<PAGE>

July 20, 2009

Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906
Attention:  Corporate Secretary

Peter T. Kissinger, Ph.D. and Candice B. Kissinger
111 Lorene Place
West Lafayette, Indiana 47906-8620

Ladies and Gentlemen:

Reference is hereby made to the solicitation of proxies (the "Proxy
Solicitation") to be conducted by Peter T. Kissinger, Ph.D. and Candice B.
Kissinger (collectively, the "Kissingers"), from the holders of shares of
common stock, no par value, of Bioanalytical Systems, Inc., an Indiana
corporation (the "Company"), to, among other things, elect four nominees of
the Kissingers to the Board of Directors of the Company (the "Company Board")
at the special meeting of the shareholders of the Company to be held on such
date as set by the Board of Directors and at any adjournments, postponements,
reschedulings and continuations thereof (the "Special Meeting").

Please be advised that I hereby consent to being nominated by the Kissingers
for election to the Company Board at the Special Meeting pursuant to the
Proxy Solicitation and hereby consent to serve as a director of the Company
if I am so elected.

Sincerely,

/s/  John B. Landis
Print Name:  John B. Landis, Ph.D.


<PAGE>


July 14, 2009

Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906
Attention:  Corporate Secretary

Peter T. Kissinger, Ph.D. and Candice B. Kissinger
111 Lorene Place
West Lafayette, Indiana 47906-8620

Ladies and Gentlemen:

Reference is hereby made to the solicitation of proxies (the "Proxy
Solicitation") to be conducted by Peter T. Kissinger, Ph.D. and Candice B.
Kissinger (collectively, the "Kissingers"), from the holders of shares of
common stock, no par value, of Bioanalytical Systems, Inc., an Indiana
corporation (the "Company"), to, among other things, elect four nominees of
the Kissingers to the Board of Directors of the Company (the "Company Board")
at the special meeting of the shareholders of the Company to be held on such
date as set by the Board of Directors and at any adjournments, postponements,
reschedulings and continuations thereof (the "Special Meeting").

Please be advised that I hereby consent to being nominated by the Kissingers
for election to the Company Board at the Special Meeting pursuant to the
Proxy Solicitation and hereby consent to serve as a director of the Company
if I am so elected.

Sincerely,

/s/  Joseph H. Broecker
Print Name:  Joseph H. Broecker


<PAGE>


29 June 2009

Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906
Attention:  Corporate Secretary

Peter T. Kissinger, Ph.D. and Candice B. Kissinger
111 Lorene Place
West Lafayette, Indiana 47906-8620

Ladies and Gentlemen:

Reference is hereby made to the solicitation of proxies (the "Proxy
Solicitation") to be conducted by Peter T. Kissinger, Ph.D. and Candice B.
Kissinger (collectively, the "Kissingers"), from the holders of shares of
common stock, no par value, of Bioanalytical Systems, Inc., an Indiana
corporation (the "Company"), to, among other things, elect four nominees of
the Kissingers to the Board of Directors of the Company (the "Company Board")
at the special meeting of the shareholders of the Company to be held on such
date as set by the Board of Directors and at any adjournments, postponements,
reschedulings and continuations thereof (the "Special Meeting").

Please be advised that I hereby consent to being nominated by the Kissingers
for election to the Company Board at the Special Meeting pursuant to the
Proxy Solicitation and hereby consent to serve as a director of the Company
if I am so elected.

Sincerely,

/s/   Candice B. Kissinger
Print Name:  Candice B. Kissinger


<PAGE>


July 15, 2009

Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906
Attention:  Corporate Secretary

Peter T. Kissinger, Ph.D. and Candice B. Kissinger
111 Lorene Place
West Lafayette, Indiana 47906-8620

Ladies and Gentlemen:

Reference is hereby made to the solicitation of proxies (the "Proxy
Solicitation") to be conducted by Peter T. Kissinger, Ph.D. and Candice B.
Kissinger (collectively, the "Kissingers"), from the holders of shares of
common stock, no par value, of Bioanalytical Systems, Inc., an Indiana
corporation (the "Company"), to, among other things, elect four nominees of
the Kissingers to the Board of Directors of the Company (the "Company Board")
at the special meeting of the shareholders of the Company to be held on such
date as set by the Board of Directors and at any adjournments, postponements,
reschedulings and continuations thereof (the "Special Meeting").

Please be advised that I hereby consent to being nominated by the Kissingers
for election to the Company Board at the Special Meeting pursuant to the
Proxy Solicitation and hereby consent to serve as a director of the Company
if I am so elected.

Sincerely,

/s/   Jerome G. Marchant
Print Name:  Jerome G. Marchant


<PAGE>


                         IMPORTANT INFORMATION

Peter T. Kissinger, Ph.D. and Candice B. Kissinger (collectively, the
"Kissingers"), together with the other participants named herein, intend to
make a preliminary filing with the Securities and Exchange Commission ("SEC")
of a proxy statement and an accompanying proxy card to be used to solicit
proxies for the removal of four of the members of the Board of Directors of
Bioanalytical Systems, Inc. (the "Company"), without cause, and for the
election of the Kissingers' slate of director nominees to replace the removed
directors at a special meeting of shareholders, to be called by the Company
at the request of the Kissingers.

THE KISSINGERS STRONGLY ADVISE ALL SHAREHOLDERS OF THE COMPANY TO READ THE
PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES
FROM SHAREHOLDERS OF THE COMPANY FOR USE AT THE SPECIAL MEETING WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING
INFORMATION RELATING TO THE PARTICIPANTS IN SUCH PROXY SOLICITATION.
When completed, a definitive proxy statement and a form of proxy will
be mailed to the Company's shareholders and will be available, along with
other relevant documents, at no charge from the participants and will also be
 available at no charge at the SEC's website at http://www.sec.gov.
Information relating to the participants in such proxy solicitation is
contained herein and will be contained in the proxy statement when it is
filed with the SEC by the Kissingers.


</TEXT>
</DOCUMENT>
